Dernières nouvelles pour Flutter Entertainment (NYSE:FLUT) Stock

Flutter Entertainment

In 2016, Irish company Paddy Power merged with UK firm Betfair to form online gaming operator Flutter Entertainment. Today, Flutter has the top digital revenue share in the US, UK and Ireland, Australia, and many other countries. Some of its main brands are FanDuel in the US, Sky Betting & Gaming and Paddy Power in the UK and Ireland, Sportsbet (acquired by Paddy Power in 2009) in Australia, and Sisal in Italy. As of Dec. 31, 2024, the company offered products in over 100 countries and had 13.9 million average monthly users. In 2024, sports betting was 56% of revenue, online gaming 40%, and fantasy sports, horse racing, and other 4%.

Flutter Entertainment plc Ordinary Shares

Flutter Entertainment PLC

Flutter Entertainment PLC ADR

The Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) Air Force One replacement program remains years behind schedule and billions over budget as workforce challenges and design complications continue plaguing production, a new report states. 
What Happened: The Government Accountability Office shared on Wednesday that &#8220;ongoing design issues, modification rework, and workforce challenges&#8221; are still delaying Boeing&#8217;s VC-25B presidential aircraft program, Fortune <a href="https://fortune.com/2025/06/13/boeing-air-force-one-delays-mechanic-labor-shortage/">reported </a>. The Pentagon confirmed to congressional auditors that Boeing continues struggling to hire and retain qualified mechanics due to competitive market conditions and security clearance approval bottlenecks, according to the GAO report.
Boeing signed a $3.9 billion contract in 2018 to deliver two modified 747-8 aircraft by 2024, but persistent delays have pushed completion to December 2029 or potentially &#8220;years beyond,&#8221; Boeing officials told Reuters in February. The program now faces projected costs of nearly $6.2 billion, representing at least $2 billion in cost overruns from the original contract.
Progress has stalled due to decompression system issues, environmental control design problems, and incomplete certification plans. Trump has eliminated requirements for air-to-air refueling capabilities to expedite delivery. Boeing CEO Kelly Ortberg revealed at a Barclays conference that the company is working with Elon Musk to resolve production bottlenecks, with Musk visiting Boeing&#8217;s San Antonio facility in December 2024. See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45921574/lockheed-martin-rtx-general-dynamics-and-other-defense-stocks-rise-in-friday-pre-market-whats-going-on">Lockheed Martin, RTX, General Dynamics And Other Defense Stocks Rise In Friday Pre-Market: What&#8217;s Going On?</a>
Why It Matters: The extended delays have forced Trump to secure alternative transportation through a controversial $400 million Boeing 747 from Qatar&#8217;s royal family. Aviation experts warn the Qatari jet conversion could <a href="https://www.benzinga.com/25/05/45404708/trumps-boeing-jet-gift-from-qatar-could-cost-taxpayers-1-billion-and-he-still-may-not-be-able-to-use-it-this-term-say-experts">cost taxpayers up to $1 billion</a> and take years to complete, potentially extending into the 2030s before meeting presidential security standards.
Boeing&#8217;s workforce challenges reflect broader industry labor shortages despite the company announcing plans to cut 10% of its workforce last fall. The VC-25B program requires mechanics with stringent security clearances, creating additional hiring constraints. Program officials noted that &#8220;approval rates for mechanics to acquire necessary clearances remain a workforce limitation.&#8221;
The Air Force One delays add to Boeing&#8217;s operational challenges amid ongoing quality control issues across its commercial aircraft programs. The company faces FAA scrutiny over safety concerns while competing with Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSF#OTC">EADSF</a>), which recently <a href="https://www.benzinga.com/markets/equities/25/06/45900237/boeing-rival-airbus-says-it-can-hit-2025-delivery-goals-amid-delays-caused-by-supply-chain-constraints">confirmed confidence in meeting its 2025 delivery targets </a>of 820 aircraft despite supply chain constraints. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45921359/fda-expands-modernas-rsv-vaccine-use-to-at-risk-adults-aged-18-59-amid-cdc-panel-shake-up">FDA Expands Moderna&#8217;s RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

EADSF

Boeing's Air Force One Overhaul Delayed Again As Workforce Woes, Design Failures And Security Bottlenecks Mount, GAO Reports

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and maintains $4 price target.

News

Price Target

Analyst Ratings

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target

President Donald Trump has never been one to hold back, but his latest jab at Federal Reserve Chair Jerome Powell might be aging worse than milk left out in the sun. Less than a day after <a href="https://www.benzinga.com/news/politics/25/06/45913481/trump-rips-jerome-powell-over-rates-but-supreme-court-shields-fed-from-firing">calling Powell a "numbskull"</a> for refusing to slash interest rates, the financial landscape has shifted dramatically—putting Trump's demand in an awkward position.
At a White House event on Thursday, Trump unleashed a tirade against Powell, frustrated that the Fed hadn't cut rates despite inflation remaining near a four-year low. For months, Trump has been pushing aggressively for lower rates, arguing that cutting them by two percentage points could save the government $600 billion a year in financing costs.
Vice President JD Vance also turned up the heat on Powell, calling the central bank's refusal to cut rates "monetary malpractice" in a June 12 post on X.
Read More: <a href="https://www.benzinga.com/news/politics/25/06/45898797/trump-and-jd-vance-push-fed-to-slash-interest-rates-after-mild-inflation-report-calling-current-policy-monetary-malpractice">Trump And JD Vance Push Fed To Slash Interest Rates After Mild Inflation Report, Calling Current Policy &#8216;Monetary Malpractice&#8217;</a>
But Powell, ever cautious, has refused to budge as the rate of consumer-price increases is still above the central bank&#8217;s 2% target. Trump has dismissed those concerns outright, insisting that inflation was under control and that the Fed could simply hike rates again later if needed.
Renewed Inflation Risk Suggests Powell&#8217;s Caution Is Justified
Well, the fear of higher inflation may have resurfaced faster than Trump anticipated. Within hours of his remarks, global crude prices surged as much as 14%, following Israel's large-scale airstrikes on Iran's nuclear infrastructure, reigniting fears of an inflationary shock. The sudden spike in crude prices threatens to ripple through the economy, pushing up costs for businesses and consumers alike—precisely the kind of scenario Powell had warned about when resisting Trump's aggressive push for rate cuts.
Peter Schiff, a well-known economist and financial commentator, weighed in on the situation in an X post on Thursday, highlighting the inflationary risks ahead.
"Since the May low, the oil price is up 30%," Schiff wrote. "Anyone hoping for lower inflation or Fed rate cuts based on falling oil prices needs to rethink their assumptions. Both oil prices and inflation will be higher under Trump than they were under Biden. Rate cuts will just fuel both fires."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Since the May low, the oil price is up 30%. Anyone hoping for lower inflation or Fed rate cuts based on falling oil prices needs to rethink their assumptions. Both oil prices and inflation will be higher under Trump than they were under Biden. Rate cuts will just fuel both fires.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1933337765787414948?ref_src=twsrc%5Etfw">June 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Will Trump Blink Or Double Down?
Schiff's warning underscores the dilemma now facing Trump. His argument for slashing rates hinged on the idea that inflation was under control—but with oil prices surging, the Fed's cautious approach looks increasingly justified. The geopolitical turmoil in the Middle East has thrown a wrench into Trump's economic playbook, making his "numbskull" insult to Powell seem premature at best.
In March 2022, Powell testified before the U.S. Senate Banking Committee that every $10 per barrel increase in crude oil prices raises U.S. headline inflation (CPI) by approximately 0.2 percentage points and sets back economic growth by 0.1 percentage points—a warning that feels increasingly relevant amid the latest oil price surge.
In a September 2021 study, the Federal Reserve Bank of Dallas examined the inflationary effects of rising oil prices. The research found that if crude prices climbed to $100 per barrel for three months, the annual inflation rate could increase by up to 3 percentage points in the short term.
As markets brace for further volatility, the question now is whether Trump will adjust his stance—or double down on his demand for rate cuts, even as inflation risks mount.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45798570/exclusive-should-fed-chair-powell-resign-heres-what-benzinga-readers-said">Should Fed Chair Powell Resign? Here&#8217;s What Benzinga Readers Said</a></li>
</ul>
Image created using photos from Shutterstock and Fed.

Macro Economic Events

Commodities

Politics

Economics

Trump's 'Numbskull' Insult Comes Back To Bite—In Record Time

- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ("MDD") with expected combined enrollment of approximately 550 participants across three studies (APPROACH&#x2122;, EMBRACE&#x2122;, and EXTEND) -
- Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities -
- Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54274168&amp;newsitemid=20250612856093&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=b33e5f4a2662caf8115f1c9d66a66bc8">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.

CYBN

Cybin Announces Patient Dosing In Phase 3 CYB003 PARADIGM Program In Major Depressive Disorder With Expected Combined Enrollment Of About 550 Participants Across Three Studies

BRTX

BioRestorative Reports Preliminary Data For FDA-Fast-Tracked BRTX-100, An Autologous Stem Cell Therapy To Treat Chronic Lumbar Disc Disease; Says Updated Data Presented At ISSCR 2025 Demonstrates >50% Improvement In Pain And Function In Significant Portion Of cLDD Subjects

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Clearone Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>)</h3>
<ul class="wp-block-list">
<li>On June 2, ClearOne announced it authorized a 1-for-15 reverse stock split. The company's stock fell around 27% over the past month and has a 52-week low of $4.35.</li>
<li>RSI Value: 17.9</li>
<li>CLRO Price Action: Shares of Clearone gained 1.6% to close at $5.80 on Thursday.</li>
<li>Edge Stock Ratings: 0.63 Momentum score with Value at 82.24. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/CLRO"><img loading="lazy" decoding="async" width="405" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207.png" alt="" class="wp-image-948444" style="width:338px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207.png 405w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207-300x135.png 300w" sizes="(max-width: 405px) 100vw, 405px" /></a></figure>
<h3 class="wp-block-heading">Cloudastructure Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 15, Cloudastructure reported $738.00 thousand in sales for the first quarter. &#8220;Cloudastructure began 2025 with substantial momentum,&#8221; said James McCormick, Chief Executive Officer of Cloudastructure. &#8220;Revenue for the quarter more than tripled year-over-year, we turned the corner on gross profit, and we secured the largest contract in our Company&#8217;s history. The demand for real time crime deterrence has never been stronger—and we are leading the charge.&#8221; The company's stock fell around 40% over the past month and <a href="https://www.benzinga.com/quote/CSAI">has a 52-week low</a> of $1.91.</li>
<li>RSI Value: 26.6</li>
<li>CSAI Price Action: Shares of Cloudastructure closed at $2.00 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613">CSAI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613"><img loading="lazy" decoding="async" width="915" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209.png" alt="" class="wp-image-948448" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209-768x688.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Digital Ally Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>)</h3>
<ul class="wp-block-list">
<li>On May 21, Digital Ally reported a year-over-year decrease in first-quarter sales results. &#8220;Our first quarter financial results, which included substantial non-operating gains and losses, clearly reflect the operating leverage inherent in our business model that has resulted from substantial decreases in overhead expenses, reduced headcount, and the focus on our subscription based sales model for our video solutions segment and the successful restructuring of our law enforcement products sales organization,&#8221; stated Stanton E. Ross, Chief Executive Officer of Digital Ally, Inc. The company's stock fell around 29% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/DGLY">low of $1.93</a>.</li>
<li>RSI Value: 25.9</li>
<li>DGLY Ltd Price Action: Shares of Digital Ally fell 3.2% to close at $2.84 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613">DGLY shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613"><img loading="lazy" decoding="async" width="888" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210.png" alt="" class="wp-image-948450" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210-768x733.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45902941/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-q2">Top 2 Defensive Stocks That May Keep You Up At Night In Q2</a></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

CLRO

CSAI

DGLY

Top 3 Tech Stocks That Are Preparing To Pump This Quarter

Benchmark analyst Cody Acree reiterates Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $170 price target.

Reiteration

Benchmark Reiterates Buy on Advanced Micro Devices, Maintains $170 Price Target

Rosenblatt analyst Hans Mosesmann maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $200 price target.

Rosenblatt Maintains Buy on Advanced Micro Devices, Maintains $200 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $50 price target.

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $50 Price Target

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $95 price target.

Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target

Needham analyst Joshua Reilly reiterates Bandwidth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) with a Buy and maintains $20 price target.

BAND

Needham Reiterates Buy on Bandwidth, Maintains $20 Price Target

Rosenblatt analyst Mike Genovese maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Buy and raises the price target from $18 to $20.

EXTR

Rosenblatt Maintains Buy on Extreme Networks, Raises Price Target to $20

&nbsp;
Two months ago I gave Iran a 60 day ultimatum to "make a deal." They should have done it! Today is day 61. I told them what to do, but they just couldn't get there. Now they have, perhaps, a second chance!
&nbsp;
&nbsp;

Global

iShares MSCI Israel Capped Investable Market Index Fund

President Trump Posts On Truth Social: 'Two months ago I gave Iran a 60 day ultimatum to "make a deal." They should have done it! Today is day 61. I told them what to do, but they just couldn't get there. Now they have, perhaps, a second chance!'

Barrington Research analyst Gary Prestopino maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and maintains $15 price target.

AIOT

Barrington Research Maintains Outperform on PowerFleet, Maintains $15 Price Target

Texas is the second‑most populous state2 in the U.S. and recorded over 323,000 home sales in 2024, with a median sale price of $347,000, representing more than $112 billion in residential transaction value3. This expansion into Texas positions reAlpha to reach millions of prospective homebuyers through a tech-enabled, streamlined platform that delivers real savings at closing, including in high-volume markets such as Dallas-Fort Worth, San Antonio, Houston, and Austin.
 &nbsp;

AIRE

reAlpha Tech Enters Texas Market With Launch Of AI-Driven Real Estate Brokerage Services

<a href="https://www.globenewswire.com/Tracker?data=sRJiU6AhBwRs7N2q0k9SUJED5c2NDl4SjhSsHUwYHRP4meEtNPhrehANOUDTP0kRW6urx4bwssPhRWmHGPipsA==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).
Details for the oral presentation are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Session Title:</td>
<td>Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1</td>
</tr>
<tr>
<td>Session Date/Time:</td>
<td>Saturday, June 21, 2025, 4:30 PM - 6:00 PM CDT</td>
</tr>
<tr>
<td>Presentation Title:</td>
<td>Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Saturday, June 21, 2025 at 5:45 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
Details of the poster presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Altimmune to Present Data on Obesity and Liver Drug Pemvidutide at Upcoming Diabetes Conference

Phillips Edison &amp; Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PECO#NASDAQ">PECO</a>) ("PECO" or the "Company"), one of the nation's largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the "Operating Partnership"), has priced a public offering of $350 million aggregate principal amount of 5.250% senior unsecured notes due 2032 (the "Notes"). The Notes were priced at 99.832% of the principal amount and will mature on August 15, 2032. The offering is expected to settle on June 17, 2025, subject to the satisfaction of customary closing conditions. The notes will be fully and unconditionally guaranteed by PECO.
The Operating Partnership intends to use the net proceeds from the offering for general corporate purposes, including to repay borrowings under its revolving credit facility, to repay its term loans and other outstanding indebtedness, to acquire additional properties, for capital expenditures, expansion and working capital, to redevelop and/or improve properties and for other general corporate purposes. Pending application of the net proceeds from the offering for the foregoing purposes, such proceeds may initially be invested in short-term securities.

PECO

Phillips Edison's Operating Partnership Prices Public Offering Of $350M Aggregate Principal Amount Of 5.250% Senior Unsecured Notes Due 2032

ASTS

AST SpaceMobile Settles Term Sheet Facilitating Long-Term Access To Up To 45 MHz Of Premium Lower Mid-Band Spectrum In North America For Direct-to-Device Satellite Applications

Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at&nbsp;5:00 p.m. Eastern Time&nbsp;on&nbsp;June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on&nbsp;May 21, 2025, with the final ratio subsequently determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Tuesday,&nbsp;June 17, 2025&nbsp;under the Company's existing trading symbol "SNSE" with the new CUSIP number 81728A207.

Stock Split

SNSE

Sensei Biotherapeutics To Implement 1-For-20 Reverse Stock Split Of Issued And Outstanding Shares, Effective June 16, 2025

Senmiao Technology Limited ("Senmiao" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/AIHS#NASDAQ">AIHS</a>), a financing and servicing company focused on the online ride-hailing industry in China, today announced that it has signed a strategic cooperation agreement (the "Agreement") with <a href="https://www.globenewswire.com/Tracker?data=JVw778hMIeG3PerOje-sevKZsnS-KaGXq6E6ME5yrktKIa1u6LtMSnlJUCJ0TEFm5fbR1E2ej7GGHMvmvfdJHkfacsuagMlltv-51zSUR8O0BAZ0bWw-g_b2pnrSZrvpSTR-GQsgbBMEPtYd3q0-aA==">Changsha Yipeng Information Technology Co., Ltd</a>. ("Changsha Yipeng") to jointly develop an AI-backed data management system aiming to improve efficiency of online ride-hailing management platforms.
Changsha Yipeng has over a decade of experience in developing integrated AI-based information systems, big data, and cloud platforms for government and private entities in China, across a variety of sectors.
Pursuant to the Agreement, Changsha Yipeng will utilize Senmiao's data (related to drivers, vehicles and riders) from its historical operating information, to develop an AI-backed data management system to facilitate the collection and analysis of data and ultimately provide online ride-hailing service providers with efficient and safe ways to operate their service vehicles. Along with the development of the project,, both parties will jointly seek necessary financing for its full development and deployment.

Comments

Flutter Entertainment

Actualités

Dernières nouvelles pour Flutter Entertainment (NYSE:FLUT) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL